arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

OCULAR THERAPEUTIX, INC

OCUL
$9.19 ▲ +0.44 (+5.03%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
55 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

OCULAR THERAPEUTIX, INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.1B
Dividend Yield
Revenue Growth 0.8%
Op. Margin None
ROIC -12.7%
FCF / Share $-0.32
Trailing P/E
Price / Book 3.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$10.79M
↑ +0.8%
Net Income Profit after all expenses
$-88.61M
↓ -38.3%
Operating Margin Operating profit as % of sales
-472.3%
↓ -59.5%
FCF / Share Free cash flow per share
$-0.32
↓ -14.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
19
Financial Health
21
Cash Quality
55

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 55 quarters